Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
Cristiano Chaves,Rafael G. dos Santos,Serdar M. Dursun,Massimo Tusconi,Mauro Giovanni Carta,Elisa Brietzke,Jaime E. C. Hallak
DOI: https://doi.org/10.3389/fpsyt.2024.1485337
IF: 4.7
2024-11-07
Frontiers in Psychiatry
Abstract:"Iracema comes with the pot full of the green liquor. The shaman decrees the dreams to each warrior and distributes the wine of jurema, which carries the brave Tabajara to heaven." José de Alencar, in his poetic novel "Iracema" (1865)1. IntroductionThe "wine of jurema", used in ancient Brazilian shamanic rituals, is rich in N,N-dimethyltryptamine (DMT), a naturally occurring tryptamine like serotonin and melatonin. Widely found in plants and animals, DMT is the main component of some botanical tisanes used for centuries as a channel of communication with the otherworld (1, 2). Despite being classified as a "classical psychedelic" (2-4), DMT's unique effects are often overlooked due to an overemphasis on serotonin (5HT) 2A receptors as the key pharmacological feature of serotoninergic psychedelics. This simplification ignores DMT's broader receptor interactions, lack of tolerance, and distinct subjective experiences. A nuanced understanding of DMT's pharmacology and its redefinition among psychedelics is necessary to recognize its full potential.DMT was originally synthesized by Canadian chemist Richard Manske in 1931, before it had ever been discovered in any plant (5), but its hallucinogenic properties were confirmed only in 1956 when chemist and psychiatrist Stephen Szara administered DMT intramuscularly to healthy volunteers, who experienced LSD-like effects (6). However, DMT had been identified earlier in Mimosa hostilis roots (the main component of the "wine of jurema") by chemist O. Gonçalves de Lima in 1946 (7) and was later recognized in 1957 as a key psychoactive ingredient in ayahuasca ("vine of the souls") (8). These brews produce intense closed-eye (and, less frequently, open-eye) visual effects, known in Portuguese as "miração" ("seeings"), with immersive dream-like states and rich internal imagery (9-11). In contrast to other serotoninergic psychedelics, individuals who use ayahuasca and DMT report stronger visual effects, breakthrough experiences, near-death experiences, and encounters with entities (12-16).This distinct phenomenology reflects DMT's unique pharmacological profile, defying its simplistic classification as a classical psychedelic. In fact, DMT (a) activates sigma-1 receptors, trace amine-associated receptors (TAAR1), and intracellular 5HT2A receptors; (b) acts as a substrate of the serotonin uptake transporter (SERT) and the vesicle monoamine transporter (VMAT2); (c) and modulates dopaminergic, noradrenergic, adrenergic and cholinergic neurotransmission (1, 4, 17-19). Unlike LSD, which induces complete tolerance after four consecutive daily doses (20), DMT's effects remain minimally reduced with repeated use (21, 22). Moreover, DMT's endogenous presence in the human body (urine, blood, cerebrospinal fluid) suggests roles in neuroplasticity, immune function, and other physiological processes, further distinguishing it from other psychedelics.In mental health treatment, an exploratory study with intravenous DMT has shown next-day antidepressant effects in treatment-resistant depression (23). Ayahuasca has been long used in traditional Amazonian ceremonies with the aim of facilitating profound introspection and emotional healing. Modern preliminary research suggests its therapeutic potential for treating mood, anxiety, substance use, and trauma-related disorders (24-35), as well as suicidality (34) – possibly by modulating emotion and trauma processing (36-41).However, these studies remain in their early stages, often involving small sample sizes and variability in methodologies. In contrast, LSD has a long tradition of studies, MDMA is approved in Australia for PTSD, and psilocybin, now also approved in Australia, shows promising potential for treatment-resistant depression. Hence, this study aims to highlight the unique characteristics of DMT that make it a promising candidate for psychedelic therapeutics.2. DMT Unique Features2.1 There is an Endogenous Production of DMTA distinguishing feature of DMT is its natural production in the human body. Although often associated with hallucinogenic experiences when administered exogenously, DMT's presence and role in the brain under normal physiological conditions remain an area of active investigation. Since the 1960s and 1970s we have known that mammals, including humans, endogenously produce DMT (18, 42, 43); for a comprehensive review, see Barker et al. (2012) (44). However, recent rodent studies show that DMT is present in the brain at levels akin to canonic neurotransmitters like serotonin and dopamine (45, 46). Early research confirmed the presence of endogenous DMT in various tissues, including the liver and lungs, using techniques like gas chromatography and mass spectrometry (43). Traditionally, DMT synthesis have been attributed to the enzyme indolethylamine N-methyltransferase (INMT) (47). Nonetheless, Glynos et al. (2023) demonstrated that INMT is not essential for DMT produ -Abstract Truncated-
psychiatry